Trial Profile
A Phase 2 Clinical Study of MM-302 in Patients with Advanced HER2 Positive Breast Cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 22 May 2014
Price :
$35
*
At a glance
- Drugs Gancotamab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 22 May 2014 New trial record
- 01 May 2014 According to a Merrimack Pharmaceuticals media release, a phase II clinical study for MM-302 will be initiated in 2014.